In glioma, it is well known that O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is both prognostic and predictive of treatment outcome with temozolomide, so treatment decisions in clinical routine for glioblastoma are mainly based on it. Here, MGMT is linked to central nervous system cancer.